Buergers Disease Market is segmented By Treatment (Medications (Vasodilators, Anticoagulants, Calcium Channel Blockers, Antiplatelet Agents) Surgical Interventions (Sympathectomy, Amputation) , Advanced Therapies (Stem Cell Therapy, Gene Therapy, Hyperbaric Oxygen Therapy)), By Route of Administration (Oral, Injectable, Topical), By End User (Hospitals, Clinics, Specialty Centers, Research Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned.
Taille du Marché en USD Mn
TCAC5.2%
Période d'Étude | 2024 - 2031 |
Année de Base de l'Estimation | 2023 |
TCAC | 5.2% |
Concentration du Marché | High |
Principaux Acteurs | AnGes Inc., Mitsubishi Tanabe Pharma Corporation, Pluristem Therapeutics Inc., Stempeutics Research Pvt. Ltd., Fuji Yakuhin Co., Ltd. and Among Others. |
The Buerger's disease market is estimated to be valued at USD 421 million in 2024 and is expected to reach USD 603 million by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031. With increasing awareness about the symptoms and risk factors, a greater number of patients are being diagnosed annually. Along with this, the availability of various treatment options and new drugs in the pipeline will contribute to the growth of the market during the forecast period.